Skip to main content
main-content

30.06.2017 | Original Research Article | Ausgabe 4/2018

Clinical Pharmacokinetics 4/2018

Prediction of the Effect of Renal Impairment on the Pharmacokinetics of New Drugs

Zeitschrift:
Clinical Pharmacokinetics > Ausgabe 4/2018
Autoren:
Elisa Borella, Italo Poggesi, Paolo Magni
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1007/​s40262-017-0574-9) contains supplementary material, which is available to authorized users.

Abstract

Introduction

Renal impairment may have a significant impact on the pharmacokinetics of drugs. Ad hoc studies in subjects with renal impairment are required by the regulatory authorities to propose dose adjustments in these subjects, to find a dosing regimen able to provide a systemic exposure similar to those in subjects with a normal renal function given the relevant clinical dose.

Methods

To evaluate the main descriptors and establish a predictive model of the effect of renal impairment on the exposure of new drugs, we considered 73 marketed drugs, for which studies in subjects with different degrees of renal impairment were available in the literature. Multivariate analysis was performed using the main pharmacokinetic parameters. Other approaches, including data mining and machine learning techniques, were tested to propose models based on a categorical definition of the exposure changes.

Results

Stepwise multivariate regression analyses revealed, as expected, that the fraction of dose excreted unchanged in urine and plasma protein binding were the factors primarily related to the change in exposure between subjects with normal and impaired renal function. Data mining techniques provided similar results.

Discussion

The pharmacokinetic predictions were however not always satisfactory, especially for drugs which, despite the negligible renal excretion, are characterized by significant increases in the systemic exposure in subjects with renal impairment. This phenomenon, interpreted considering the accumulation of endogenous metabolism inhibitors in subjects with moderate and severe renal disease (uremic toxins), cannot be fully captured and described, likely owing to an incomplete understanding of the pathophysiological phenomena and to some limitations of the available database of clinical studies.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Zusatzmaterial
Supplementary material 1 (XLSX 17 kb)
40262_2017_574_MOESM1_ESM.xlsx
Supplementary material 2 (PDF 463 kb)
40262_2017_574_MOESM2_ESM.pdf
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 4/2018

Clinical Pharmacokinetics 4/2018 Zur Ausgabe